Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers

被引:214
作者
Ferrari, G
Humphrey, W
McElrath, MJ
Excler, JL
Duliege, AM
Clements, ML
Corey, LC
Bolognesi, DP
Weinhold, KJ
机构
[1] DUKE UNIV, MED CTR, DEPT SURG, DURHAM, NC 27710 USA
[2] DUKE UNIV, MED CTR, DEPT MICROBIOL, DURHAM, NC 27710 USA
[3] DUKE UNIV, MED CTR, DEPT IMMUNOL, DURHAM, NC 27710 USA
[4] UNIV WASHINGTON, DEPT MED, SEATTLE, WA 98195 USA
[5] PASTEUR MERIEUX CONNAUGHT LABS, F-92430 MARNES LA COQUETTE, FRANCE
[6] JOHNS HOPKINS UNIV, CTR IMMUNIZAT RES, BALTIMORE, MD 21205 USA
[7] CHIRON CORP, VACCINES, EMERYVILLE, CA 94608 USA
关键词
D O I
10.1073/pnas.94.4.1396
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
A fundamental goal of current strategies to develop an efficacious vaccine for AIDS is the elicitation of broadly reactive cytotoxic T lymphocyte (CTL) reactivities capable of destroying virally infected targets, Recent application of recombinant canarypox ALVAC/HIV-1 vectors as vaccine immunogens in HIV-1, -noninfected volunteers has produced CTL responses in a significant number of vaccinees, Using a newly developed targeting strategy, we examined the capacity of vaccine-induced CTL to lyse autologous targets infected with a diverse group of viral isolates. CTL derived from recipients of a canarypox ALVAC/HIV-1 gp160 (MN) vaccine were found capable of lysing autologous CD4(+) lymphoblasts infected with the prototypic LAI strain of HIV-1. When tested against autologous targets infected with primary HIV-1 isolates representing genetically diverse vira clades, CTL from ALVAC/gp160 recipients showed both a broad pattern of cytolysis in which viruses from all clades tested were recognized as well as a highly restricted pattern in which no primary isolates, including clade B, were lysed, Differences in the HLA haplotypes of the volunteers immunized with the envelope vector might be a major determinant of the relative breadth of their CTL response, In contrast to ALVAC/gp160 vaccinees, recipients of the ALVAC/HIV-1 immunogen containing envelope as well as gag and protease genes consistently had CTL reactivities effective against a spectrum of primary isolate-infected targets, These studies demonstrate for the first time that clade B-based canarypox vaccines can elicit broad CTL reactivities capable of recognizing viruses belonging to genetically diverse HIV-1 clades, The results also reinforce the impact of viral core elements in the vaccine as well as the pattern of major histocompatibility complex class I allelic expression by the vaccine recipient in determining the relative breadth of the cellular response.
引用
收藏
页码:1396 / 1401
页数:6
相关论文
共 43 条
  • [21] Safety and immunogenicity of Env 2-3, a human immunodeficiency virus type 1 candidate vaccine, in combination with a novel adjuvant, MTP-PE/MF59
    Keefer, MC
    Graham, BS
    McElrath, MJ
    Matthews, TJ
    Stablein, DM
    Corey, L
    Wright, PF
    Lawrence, D
    Fast, PE
    Weinhold, K
    Hsieh, RH
    Chernoff, D
    Dekker, C
    Dolin, R
    [J]. AIDS RESEARCH AND HUMAN RETROVIRUSES, 1996, 12 (08) : 683 - 693
  • [22] KINETICS OF GAG-SPECIFIC CYTOTOXIC T-LYMPHOCYTE RESPONSES DURING THE CLINICAL COURSE OF HIV-1 INFECTION - A LONGITUDINAL ANALYSIS OF RAPID PROGRESSORS AND LONG-TERM ASYMPTOMATICS
    KLEIN, MR
    VANBAALEN, CA
    HOLWERDA, AM
    KERKHOFGARDE, SR
    BENDE, RJ
    KEET, IPM
    EEFTINCKSCHATTENKERK, JKM
    OSTERHAUS, ADME
    SCHUITEMAKER, H
    MIEDEMA, F
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1995, 181 (04) : 1365 - 1372
  • [23] KORBER B, 1995, HIV MOL IMMUNOLOGY D
  • [24] TEMPORAL ASSOCIATION OF CELLULAR IMMUNE-RESPONSES WITH THE INITIAL CONTROL OF VIREMIA IN PRIMARY HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 SYNDROME
    KOUP, RA
    SAFRIT, JT
    CAO, YZ
    ANDREWS, CA
    MCLEOD, G
    BORKOWSKY, W
    FARTHING, C
    HO, DD
    [J]. JOURNAL OF VIROLOGY, 1994, 68 (07) : 4650 - 4655
  • [25] Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1
    Mascola, JR
    Snyder, SW
    Weislow, OS
    Belay, SM
    Belshe, RB
    Schwartz, DH
    Clements, ML
    Dolin, R
    Graham, BS
    Gorse, GJ
    Keefer, MC
    McElrath, MJ
    Walker, MC
    Wagner, KF
    McNeil, JG
    McCutchan, FE
    Burke, DS
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1996, 173 (02) : 340 - 348
  • [26] IMMUNE-RESPONSES ELICITED BY RECOMBINANT VACCINIA HUMAN-IMMUNODEFICIENCY-VIRUS (HIV) ENVELOPE AND HIV ENVELOPE PROTEIN - ANALYSIS OF THE DURABILITY OF RESPONSES AND EFFECT OF REPEATED BOOSTING
    MCELRATH, MJ
    COREY, L
    BERGER, D
    HOFFMAN, MC
    KLUCKING, S
    DRAGAVON, J
    PETERSON, E
    GREENBERG, PD
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1994, 169 (01) : 41 - 47
  • [27] CYTO-TOXIC T-CELL IMMUNITY TO INFLUENZA
    MCMICHAEL, AJ
    GOTCH, FM
    NOBLE, GR
    BEARE, PAS
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1983, 309 (01) : 13 - 17
  • [28] MCMICHAEL AJ, 1994, AIDS S1, V8, pS155
  • [29] HIV-1 GAG-SPECIFIC CYTO-TOXIC LYMPHOCYTES-T DEFINED WITH RECOMBINANT VACCINIA VIRUS AND SYNTHETIC PEPTIDES
    NIXON, DF
    TOWNSEND, ARM
    ELVIN, JG
    RIZZA, CR
    GALLWEY, J
    MCMICHAEL, AJ
    [J]. NATURE, 1988, 336 (6198) : 484 - 487
  • [30] NIXON DF, 1991, AIDS, V5, P1049